MLTX — MoonLake Immunotherapeutics | XLV Holdings | StockAdder

(MLTX)

MoonLake Immunotherapeutics

Live chart and latest MLTX stock news.

Sector ETF → XLV Health Care Select

Chart powered byTradingView— professional charts for every trader.Try it free →

MLTX News

MoonLake Immunotherapeutics (NASDAQ: MLTX) CEO sells 150,000 company shares

Apr 14, 2026 Yahoo Finance

How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis Suppurativa

Apr 5, 2026 simplywall.st

Assessing MoonLake Immunotherapeutics (MLTX) Valuation After A Premium Price To Book Multiple And Recent Share Moves

Mar 31, 2026 Stock Traders Daily

Precision Trading with Moonlake Immunotherapeutics (MLTX) Risk Zones

Mar 31, 2026 Investing.com

Moonlake Immunotherapeutics stock upgraded to Buy at BTIG on FDA feedback

Jan 9, 2026 The Motley Fool

Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares

Apr 7, 2026 Forbes

Moonlake: What’s Happening With MLTX Stock?

Sep 29, 2025 Investor's Business Daily

MoonLake Catapults On FDA Deal For Its Down-And-Out Skin Disease Drug

Jan 8, 2026 Stock Titan

Pre-planned MoonLake (NASDAQ: MLTX) CFO share sale totals 87,795

Apr 10, 2026 Yahoo Finance

MoonLake Immunotherapeutics (MLTX) Is Down 6.7% After Mixed 2025 Results And AxSpA Data Update - What's Changed

Feb 28, 2026 simplywall.st

How MoonLake’s Phase 3 Sonelokimab HiSCR75 Data in HS Could Shape MoonLake Immunotherapeutics (MLTX) Investors

Apr 7, 2026 Investing.com

Clear Street raises Moonlake stock price target on IL-17 data

Mar 11, 2026 Stock Titan

MoonLake Immunotherapeutics (NASDAQ: MLTX) files Form 144 to report Class A resale intent

Apr 10, 2026 Yahoo Finance

MoonLake Immunotherapeutics (MLTX): Assessing Valuation Following Phase 3 Trial Miss and Legal Scrutiny

Oct 4, 2025 Yahoo Finance

MoonLake Immunotherapeutics (MLTX) Valuation Check After Mixed Share Price Performance